Therefore, using FDA approved nanotechnology, chemical adjuvant and bio-degradable and low toxic peptide conjugation, such as liposomes, maleimide, which frequently regarded as ADC linker and peptide, respectively, to rescue candidate drugs, offering a new strategy for drug development with potential in clinical use
YamashitaYOkamotoMIkedaMOkamotoASakaiMGunjiYet al
Hence, we determined if the decreased cellular viability and increased ROS caused by LCS3 in VRK2-deficient cells could be partly explained by TXNRD1 inhibition
IGF-1 DES shows moderately reduced IGFBP affinity, with greater selectivity it particularly reduces affinity for IGFBP-1, IGFBP-2, and IGFBP-4, but retains more binding to IGFBP-3 than IGF-1 LR3 does